vs
Side-by-side financial comparison of ARGENX SE (ARGX) and BioNTech SE (BNTX). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $1.5B, roughly 1.6× BioNTech SE). ARGENX SE runs the higher net margin — 35.5% vs -1.9%, a 37.4% gap on every dollar of revenue.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
ARGX vs BNTX — Head-to-Head
Income Statement — Q4 2025 vs Q3 2025
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $1.5B |
| Net Profit | $877.2M | $-28.7M |
| Gross Margin | 89.5% | — |
| Operating Margin | 28.9% | -3.1% |
| Net Margin | 35.5% | -1.9% |
| Revenue YoY | 83.2% | — |
| Net Profit YoY | 1.3% | — |
| EPS (diluted) | $13.25 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5B | — | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $1.8B | $260.8M | ||
| Q1 25 | — | $182.8M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $901.9M | $128.7M | ||
| Q1 24 | — | $187.6M |
| Q4 25 | $877.2M | — | ||
| Q3 25 | — | $-28.7M | ||
| Q2 25 | $414.8M | $-386.6M | ||
| Q1 25 | — | $-415.8M | ||
| Q4 24 | $865.6M | — | ||
| Q3 24 | — | $198.1M | ||
| Q2 24 | $-32.5M | — | ||
| Q1 24 | — | — |
| Q4 25 | 89.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 90.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 89.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | 28.9% | — | ||
| Q3 25 | — | -3.1% | ||
| Q2 25 | 19.2% | -192.1% | ||
| Q1 25 | — | -292.2% | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | -15.4% | -750.7% | ||
| Q1 24 | — | -270.4% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | — | -1.9% | ||
| Q2 25 | 23.4% | -148.2% | ||
| Q1 25 | — | -227.5% | ||
| Q4 24 | 64.1% | — | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | — | — |
| Q4 25 | $13.25 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $6.32 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $13.33 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3B | — |
| Total Assets | $8.7B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $11.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | $7.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $6.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | — | — |
| Q4 25 | $8.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.2B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $6.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | — |
| Free Cash FlowOCF − Capex | $322.4M | — |
| FCF MarginFCF / Revenue | 13.0% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 0.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $323.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $361.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $41.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-124.7M | — | ||
| Q1 24 | — | — |
| Q4 25 | $322.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $356.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $40.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-125.5M | — | ||
| Q1 24 | — | — |
| Q4 25 | 13.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 20.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.87× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
